Axcelead Drug Discovery Partners, Inc.

Axcelead Drug Discovery Partners, Inc. supports drug research and development. With in-house research facilities, the company provides a wide range of non-clinical studies in various areas, such as immunology, safety, and pharmacokinetics. Axcelead is also known for its ability to make precise, science-based proposals from the early stages of drug discovery with a clear focus on clinical development.

Features of Axcelead’s Contract Non-Clinical Study Services

Comprehensive Packages for Non-Clinical Safety Evaluation

Axcelead offers packaged services for total support in non-clinical safety evaluation, including both GLP and non-GLP studies. The company provides integrated support toward IND submissions and out-licensing, working closely with its pharmacology and pharmacokinetics teams. This collaboration enables precise interpretation of safety margins, effective management of toxicity issues, and full assistance with regulatory submissions to PMDA or FDA.

Leveraging decades of drug discovery experience, Axcelead offers studies that optimize both cost and speed.

Strategic Non-Clinical Development Consulting by Experienced Experts

Axcelead’s consultants have deep understanding in pharmacology, synthesis, pharmacokinetics, and safety evaluation. They support the designing, execution, and analysis of non-clinical studies aligned with development strategies. They have knowledge and expertise from more than 100 IND applications and over 20 NDA submissions. The company’s strong partnerships with affiliated CROs also enable flexible and rapid trial management.

From early-stage research to pre-submission phase, Axcelead provides practical, hands-on support tailored to each client’s needs.

Comprehensive PK/PD and Pharmacokinetic Analysis Services

Axcelead has a dedicated pharmacokinetics department, which offers end-to-end PK (pharmacokinetics) and PD (pharmacodynamics) studies at the preclinical stage. Using both in vitro and in vivo studies, the company offers precise analyses of absorption, distribution, metabolism, and excretion (ADME) profiles.

Advanced technologies such as biomarker measurement, microtracer methods, and AMS (Accelerator Mass Spectrometry) can also be utilized to ensure a smooth transition from preclinical to clinical trials.

Example of a Disease Model Owned by Axcelead Drug Discovery Partners, Inc.

AXCC Mouse (Chronic Kidney Disease Model)

Axcelead has developed the “AXCC mouse,” an original model that exhibits pathology similar in patients with chronic kidney disease. This model carries the Col4a5 R471X mutation derived from Alport syndrome and shows albuminuria from 5 weeks of age, progressing through tubulointerstitial damage with fibrosis and decreased renal function, ultimately leading to renal failure.

Because this model can reliably detect drug efficacy against clinically used ARBs (angiotensin II receptor blockers) and reproduce disease pathology, it is often utilized for in vivo screening and biomarker discovery in chronic kidney disease research.

Reference URL:https://www.axcelead.com/author/sm_orderaxcelead-com/

Axcelead’s Non-Clinical Study Examples

Use of Tumor Immune Profiling in Oncology Research

In cancer immunology, Axcelead conducts preclinical studies with tumor immune profiling. By performing multifaceted analyses of immune cell spatial distribution and gene expression, the company can thoroughly evaluate the effects of drugs on the tumor microenvironment.

For example, by combining single-nucleus RNA sequencing and multiplex immunostaining techniques, Axcelead visualizes and quantifies immune responses—supporting the evaluation of therapeutic efficacy and safety.

Reference URL:https://www.axcelead.com/service/8226/?ref=sg

Company Information